• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Apogee Therapeutics Inc.

    7/8/26 12:59:14 PM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $APGE alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 5)


    Apogee Therapeutics, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)




    03770N101

    (CUSIP Number)
    06/30/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    03770N101


    1Names of Reporting Persons

    Wellington Management Group LLP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    MASSACHUSETTS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    452,388.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    564,326.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    564,326.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.9 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP Number(s):
    03770N101


    1Names of Reporting Persons

    Wellington Group Holdings LLP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    452,388.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    564,326.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    564,326.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.9 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP Number(s):
    03770N101


    1Names of Reporting Persons

    Wellington Investment Advisors Holdings LLP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    452,388.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    564,326.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    564,326.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.9 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Apogee Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    221 Crescent St, Building 17, Suite 102B, Waltham MA 02453
    Item 2. 
    (a)Name of person filing:

    Wellington Management Group LLP Wellington Group Holdings LLP Wellington Investment Advisors Holdings LLP
    (b)Address or principal business office or, if none, residence:

    c/o Wellington Management Company LLP, 280 Congress Street, Boston MA 02210
    (c)Citizenship:

    Wellington Management Group LLP - Massachusetts Wellington Group Holdings LLP - Delaware Wellington Investment Advisors Holdings LLP - Delaware
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    03770N101
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See the responses to Item 9 on the attached cover pages.
    (b)Percent of class:

    0.91  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    See the responses to Item 6 on the attached cover pages.

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    See the responses to Item 8 on the attached cover pages.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The securities as to which this Schedule is filed are owned of record by clients of one or more investment advisers identified in Item 7 directly or indirectly owned by Wellington Management Group LLP. Those clients have the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of, such securities. No such client is known to have such right or power with respect to more than five percent of this class of securities, except as follows: Not Applicable.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    Pursuant to the instructions in Item 7 of Schedule 13G, the following lists the identity and Item 3 classification of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Wellington Group Holdings LLP - HC Wellington Investment Advisors LLP - HC Wellington Management Global Holdings, Ltd. - HC One or more of the following investment advisers (the "Wellington Investment Advisers"): Wellington Management Company LLP - IA Wellington Management Canada LLC - IA Wellington Management Singapore Pte Ltd - IA Wellington Management Hong Kong Ltd - IA Wellington Management International Ltd - IA Wellington Management Japan Pte Ltd - IA Wellington Management Australia Pty Ltd - IA The securities as to which this Schedule is filed by Wellington Management Group LLP, as parent holding company of certain holding companies and the Wellington Investment Advisers, are owned of record by clients of the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP controls directly, or indirectly through Wellington Management Global Holdings, Ltd., the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP is owned by Wellington Group Holdings LLP. Wellington Group Holdings LLP is owned by Wellington Management Group LLP.
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Wellington Management Group LLP
     
    Signature:Matthew Revell
    Name/Title:Compliance Manager
    Date:07/08/2026
     
    Wellington Group Holdings LLP
     
    Signature:Matthew Revell
    Name/Title:Compliance Manager
    Date:07/08/2026
     
    Wellington Investment Advisors Holdings LLP
     
    Signature:Matthew Revell
    Name/Title:Compliance Manager
    Date:07/08/2026
    Get the next $APGE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APGE

    DatePrice TargetRatingAnalyst
    5/1/2026$140.00Buy
    Rothschild & Co Redburn
    3/18/2026$83.00Hold
    Truist
    1/22/2026$83.00Outperform → Sector Perform
    RBC Capital Mkts
    1/7/2026Peer Perform
    Wolfe Research
    12/17/2025$95.00Overweight
    Stephens
    12/10/2025$103.00Buy
    Deutsche Bank
    11/3/2025$109.00Buy
    Craig Hallum
    10/21/2025$105.00Outperform
    Mizuho
    More analyst ratings

    $APGE
    SEC Filings

    View All

    SEC Form DEFM14A filed by Apogee Therapeutics Inc.

    DEFM14A - Apogee Therapeutics, Inc. (0001974640) (Filer)

    7/13/26 5:15:12 PM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Apogee Therapeutics Inc.

    SCHEDULE 13G/A - Apogee Therapeutics, Inc. (0001974640) (Subject)

    7/8/26 12:59:14 PM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Apogee Therapeutics Inc.

    SCHEDULE 13G/A - Apogee Therapeutics, Inc. (0001974640) (Subject)

    7/8/26 11:30:22 AM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APGE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mckenna Mark C. bought $990,775 worth of shares (20,000 units at $49.54) (SEC Form 4)

    4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)

    12/16/24 6:00:10 AM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APGE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Dambkowski Carl gifted 8,000 shares, decreasing direct ownership by 4% to 169,873 units (SEC Form 4)

    4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)

    7/16/26 8:00:13 PM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Henderson Michael Thomas sold $2,672,600 worth of shares (20,000 units at $133.63) as part of a pre-agreed trading plan and gifted 75,046 shares, decreasing direct ownership by 9% to 920,941 units (SEC Form 4)

    4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)

    7/10/26 8:00:17 PM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Medical Officer Dambkowski Carl sold $730,070 worth of shares (5,500 units at $132.74) as part of a pre-agreed trading plan and exercised 4,125 shares at a strike of $22.86, decreasing direct ownership by 0.77% to 177,873 units (SEC Form 4)

    4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)

    7/2/26 8:13:06 PM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APGE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $APGE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio

    Proposed acquisition adds a diverse pipeline of assets focused on elevating the standard of care for patients with dermatologic, respiratory and other related inflammatory and immunological diseasesApogee's lead asset, zumilokibart (APG777), is a late-stage, half-life extended monoclonal antibody targeting IL-13, in development for patients with atopic dermatitisApogee's pipeline also includes combinations of its novel antibodies; APG273, a potential best-in-category long-acting combination targeting IL-13 and thymic stromal lymphopoietin (TSLP), is being developed in asthmaApogee shareholders to receive $135.11 per share in cash, for a total equity value of approximately $10.9 billionAbbVie

    6/22/26 7:00:00 AM ET
    $ABBV
    $APGE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Apogee Therapeutics to Participate in Upcoming June Conferences

    SAN FRANCISCO and BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), today announced that members of management will participate at the following investor conferences. Jefferies Global Healthcare Conference Date: Wednesday, June 3, 2026Fireside Time: 11:40 a.m. ET Goldman Sachs 47th Annual Global Healthcare ConferenceDate: Wednesday, June 10, 2026Fireside Time: 9:20 a.m. ET A live and archived webcast of the fireside chats will be available via the News & Events page in the Investors section of the Apogee Therapeutics website. About ApogeeApogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentia

    5/28/26 4:01:00 PM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Apogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of Zumilokibart

    Up to $1.3 billion in flexible, non-dilutive capital, including up to $800 million of synthetic royalty and access of up to $500 million in senior corporate debt  Combined with company's current total cash of $1.3 billion, this transaction positions Apogee to achieve a self-sustainable financial profile through commercialization of zumilokibart without need for future equity financing Apogee to host webcast with the APEX Phase 2 Part B results today at 8:00 a.m. Eastern Time SAN FRANCISCO and BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class pr

    5/27/26 6:31:00 AM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Rothschild & Co Redburn initiated coverage on Apogee Therapeutics with a new price target

    Rothschild & Co Redburn initiated coverage of Apogee Therapeutics with a rating of Buy and set a new price target of $140.00

    5/1/26 7:32:03 AM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Truist initiated coverage on Apogee Therapeutics with a new price target

    Truist initiated coverage of Apogee Therapeutics with a rating of Hold and set a new price target of $83.00

    3/18/26 8:22:50 AM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Apogee Therapeutics downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded Apogee Therapeutics from Outperform to Sector Perform and set a new price target of $83.00

    1/22/26 8:24:52 AM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APGE
    Leadership Updates

    Live Leadership Updates

    View All

    Apogee Therapeutics Announces Agenda for Virtual R&D Day

    SAN FRANCISCO and WALTHAM, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced the agenda for its upcoming virtual R&D Day being held on Monday, December 2, 2024 at 10:00 a.m. ET. Featured Speakers:Members of the Apogee management team will be joined by key opinion leaders (KOLs) who will discuss the current landscape and need for new t

    11/29/24 1:00:00 PM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024

    SAN FRANCISCO and WALTHAM, Mass., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced that it will host its virtual R&D Day at 10:00 a.m. ET on Monday, December 2, 2024. The event will include presentations from management discussing updates across Apogee's programs, highlighting APG777's best-in-class potential in AD, the significant role of

    11/18/24 7:30:00 AM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer

    SAN FRANCISCO and WALTHAM, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease and other I&I indications, today announced the appointment of Jeff S. Hartness as Chief Commercial Officer. Mr. Hartness has an extensive track record in commercial and corporate leadership, bringing more than 25 years of experience in the biotech industry focused on product launches, market access strategy,

    9/9/24 7:00:00 AM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APGE
    Financials

    Live finance-specific insights

    View All

    AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio

    Proposed acquisition adds a diverse pipeline of assets focused on elevating the standard of care for patients with dermatologic, respiratory and other related inflammatory and immunological diseasesApogee's lead asset, zumilokibart (APG777), is a late-stage, half-life extended monoclonal antibody targeting IL-13, in development for patients with atopic dermatitisApogee's pipeline also includes combinations of its novel antibodies; APG273, a potential best-in-category long-acting combination targeting IL-13 and thymic stromal lymphopoietin (TSLP), is being developed in asthmaApogee shareholders to receive $135.11 per share in cash, for a total equity value of approximately $10.9 billionAbbVie

    6/22/26 7:00:00 AM ET
    $ABBV
    $APGE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitis

    APEX Part B met all primary and secondary endpoints with high statistical significance; mid-dose zumilokibart planned to advance into Phase 3 trials in moderate-to-severe atopic dermatitis (AD) in 2H 2026 Zumilokibart was well tolerated with a safety profile consistent with other agents in class Strategic financing collaboration with Blackstone Life Sciences announced today expected to provide funding through commercialization of zumilokibart in AD, asthma, and EoE Results support pipeline-in-a-product potential for zumilokibart with asthma and eosinophilic esophagitis (EoE) trial plans shared today Management to host conference call today at 8:00 a.m. ET SAN FRANCISCO and BOSTON, May

    5/27/26 6:30:00 AM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Apogee Therapeutics to Host Conference Call to Report Part B 16-Week Data from the Phase 2 APEX Trial of Zumilokibart in Patients with Moderate-to-Severe Atopic Dermatitis on May 27, 2026

    SAN FRANCISCO and BOSTON, May 26, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced it will report Part B 16-week data from the Phase 2 APEX trial of zumilokibart on Wednesday, May 27, 2026. Following the announcement, the company will host a conference call and webcast at 8:00 a.m. ET to discuss the results. Webcast Details Apogee Therapeutics' live webcast of the Phase 2 APEX Part B results will begin on Wednesday, May 27 at 8:00 a.m. ET. The live webcast can be accessed via this l

    5/26/26 4:01:00 PM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APGE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Apogee Therapeutics Inc.

    SC 13G/A - Apogee Therapeutics, Inc. (0001974640) (Subject)

    11/14/24 5:46:11 PM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Apogee Therapeutics Inc.

    SC 13G - Apogee Therapeutics, Inc. (0001974640) (Subject)

    11/14/24 11:16:12 AM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Apogee Therapeutics Inc.

    SC 13G/A - Apogee Therapeutics, Inc. (0001974640) (Subject)

    11/14/24 10:18:32 AM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care